Thursday, May 31, 2018

Ways to cure sundowning

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

University of Cambridge

Early-evening restlessness and agitation, known as 'sundowning', is common in Alzheimer's. So is fragmented sleep. A major discovery indicates these symptoms are curable. 




People with Alzheimer's often have poor biological rhythms, something that is a burden for both patients and their carers. Periods of sleep become shorter and more fragmented, resulting in periods of wakefulness at night and snoozing during the day. They can also become restless and agitated in the late afternoon and early evening, something known as 'sundowning'.

The fly brain is half a millimeter across and contains approximately 100,000 nerve cells (green). The A-beta peptide forms plaques (red) that are linked to nerve cell death and behavioral abnormalities in the flies. Credit: Dr. Stanislav Ott, Department of Genetics, University of Cambridge
Now, scientists from Cambridge have discovered that in fruit flies with Alzheimer's the biological clock is still ticking but has become uncoupled from the sleep-wake cycle it usually regulates. The findings -- published in Disease Models & Mechanisms -- could help develop more effective ways to improve sleep patterns in people with the disease.

Biological clocks go hand in hand with life, and are found in everything from single celled organisms to fruit flies and humans. They are vital because they allow organisms to synchronise their biology to the day-night changes in their environments.

Until now, however, it has been unclear how Alzheimer's disrupts the biological clock. According to Dr Damian Crowther of Cambridge's Department of Genetics, one of the study's authors: "We wanted to know whether people with Alzheimer's disease have a poor behavioural rhythm because they have a clock that's stopped ticking or they have stopped responding to the clock."

The team worked with fruit flies -- a key species for studying Alzheimer's. Evidence suggests that the A-beta peptide, a protein, is behind at least the initial stages of the disease in humans. This has been replicated in fruit flies by introducing the human gene that produces this peptide.

Taking a group of healthy flies and a group with this feature of Alzheimer's, the researchers studied sleep-wake patterns in the flies, and how well their biological clocks were working.

They measured sleep-wake patterns by fitting a small infrared beam, similar to movement sensors in burglar alarms, to the glass tubes housing the flies. When the flies were awake and moving, they broke the beam and these breaks in the beam were counted and recorded.

To study the flies' biological clocks, the researchers attached the protein luciferase -- an enzyme that emits light -- to one of the proteins that forms part of the biological clock. Levels of the protein rise and fall during the night and day, and the glowing protein provided a way of tracing the flies' internal clock.

"This lets us see the brain glowing brighter at night and less during the day, and that's the biological clock shown as a glowing brain. It's beautiful to be able to study first hand in the same organism the molecular working of the clock and the corresponding behaviours," Dr Crowther said.

They found that healthy flies were active during the day and slept at night, whereas those with Alzheimer's sleep and wake randomly. Crucially, however, the diurnal patterns of the luciferase-tagged protein were the same in both healthy and diseased flies, showing that the biological clock still ticks in flies with Alzheimer's.

"Until now, the prevailing view was that Alzheimer's destroyed the biological clock," said Crowther.

"What we have shown in flies with Alzheimer's is that the clock is still ticking but is being ignored by other parts of the brain and body that govern behaviour. If we can understand this, it could help us develop new therapies to tackle sleep disturbances in people with Alzheimer's."

Dr Simon Ridley, Head of Research at Alzheimer's Research UK, who helped to fund the study, said: "Understanding the biology behind distressing symptoms like sleep problems is important to guide the development of new approaches to manage or treat them. This study sheds more light on the how features of Alzheimer's can affect the molecular mechanisms controlling sleep-wake cycles in flies.

"We hope these results can guide further studies in people to ensure that progress is made for the half a million people in the UK with the disease."


Source:
Journal Reference:
  1. K.-F. Chen, B. Possidente, D. A. Lomas, D. C. Crowther. The central molecular clock is robust in the face of behavioural arrhythmia in a Drosophila model of Alzheimer's diseaseDisease Models & Mechanisms, 2014; DOI:10.1242/dmm.014134

Tuesday, May 29, 2018

Dementia impacts people later

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

University of Texas Health Science Center at San Antonio

A new study shows dementia's impact compressing a bit. People seem to be developing dementia later, living longer while suffering for less time. 




A recently released study, included in a special supplement to the Journal of Gerontology, indicates that dementia's impact might be compressing a bit. That is, people might be developing dementia later and living with it for a shorter period of time. 

Sudha Seshadri, M.D., professor of neurology and founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases at UT Health San Antonio, is the senior author on the study, which draws evidence from the Framingham Heart Study. 

In data from four different time periods over a period of 30 years, the mean age at dementia onset increased, while the length of time living with dementia decreased. Is it because prevention and care of stroke today is superior compared to decades ago? Stroke is a major risk factor for dementia. 

"Prevention of stroke and reduced impact of stroke are great advances, but neither completely explains the trend we are seeing," Dr. Seshadri said. "We are looking at other causes, such as lower burden of multiple infections because of vaccination, and possibly lower levels of lead or other pollutants in the atmosphere. Early education and nutrition might also play a role." 

Stroke risk has decreased because of greater control of blood pressure. Dr. Seshadri again cited Framingham data: "In the past, if you had a stroke you were at 90 percent greater risk to develop dementia. Today, you have a 40 percent greater risk," she said. 


REFERENCE:

SOURCE:

Sunday, May 27, 2018

Chocolate for dementia

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Take cocoa's flavanol phytonutrients, leave out the sugar and fat, and you get a health food that improves arterial function. That's a great way to fight strokes and atherosclerosis, common triggers of vascular dementia. See NutritionFacts.org analyze the latest research. 




TRANSCRIPT:Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video. 

The problem with publishing research on chocolate is that the press jumps on it, oversimplifying and sensationalizing the message. Then, the money starts rolling in from candy companies, muddying the message. But, lost in all that is an important idea—that the flavanol phytonutrients in cocoa do appear to be beneficial. 


The sugar in chocolate isn’t good for us; the fat and excess calories in chocolate aren’t good for us; but, “natural cocoa powder can be [considered] a health food.” So, adding cocoa to a smoothie, or oatmeal, or whatever, would be health-promoting. But, ideally, choose unprocessed, un-Dutched cocoa, since the flavanols are what give cocoa its bitterness. So, they try to process cocoa with alkali to destroy them, on purpose. Thus, when it comes to cocoa, “bitter [appears to be] better.” 

In my video on chocolate and artery function, I showed how dark chocolate could improve the function of coronary arteries in the heart within two hours of consumption, using fancy angiography. But, there are some blood vessels you can visualize with your eyes—the blood vessels in your eyes. Two hours after eating dark chocolate; significant improvement in the ability of the little veins in your eyes to dilate. 

What about the blood vessels in your legs? Peripheral artery disease—atherosclerosis in the arteries feeding your limbs, leading to claudication, a crampy pain in your calf muscles when you try to exercise, due to impaired blood flow. So, maximal walking distance and maximal walking time were studied in 20 peripheral artery disease patients, two hours after eating dark chocolate, with a respectable 85+% cocoa, or after eating wimpy milk chocolate. After the dark chocolate, they could walk about a dozen more yards, and about 17 more seconds, than before the dark chocolate. 

But, after the milk chocolate they weren’t even able to walk as far as baseline, and not a single second more. So, there does seem to be something in cocoa that’s helping, but a few seconds here or there aren’t going to cut it. 

How about reversing the atherosclerosis—which we didn’t even think possible, until 1977? Wait—what happened in ’77? Dean Ornish didn’t start publishing on heart disease reversal until 1979. Well, actually, the first demonstration of atherosclerosis reversal with a cholesterol-lowering diet and drugs wasn’t on the coronary arteries going to the heart, but rather the femoral arteries, going to the legs. 

What about the arteries going to the brain? Well, there’s a noninvasive way to measure arterial function within the brain, using transcranial ultrasound. If you ask someone to hold their breath, the brain says uh-oh, and starts opening up the arteries to increase blood flow to compensate. But, if the arteries in our brain are stiffened and crippled by atherosclerosis, they’re unable to open as much and as fast as they should—and so, are said to have a smaller “breath holding index,” which can be a risk factor for stroke. So, researchers designed an experiment in which they compared the results of a target food to something neutral, like oatmeal. So, did they choose like a spoonful of cocoa powder, or something? No. A randomized crossover trial of oatmeal, versus a “deep-fried Mars bar.” 

Wait, why a deep-fried Mars bar? Well, this was published in the Scottish Medical Journal, and, evidently, deep-fried Mars bars are “a snack…strongly [associated] with Scotland.” Wait, is this just an urban legend, or something? No. “627 fish and chip shops in Scotland [were called] to ascertain the delicacy’s availability,” and more than one in five said yeah, we’re selling up to 200 a week. Just follow the signs. Comes out a little something like this. Batter-dipped and deep-dried Snickers bars and pizza were, evidently, less popular. The researchers conclude that it’s “not just an urban [legend]. Encouragingly, [they] did find some evidence of the penetrance of the Mediterranean diet…albeit in the form of deep-fried pizza.” 

Could this be contributing to Scotland having among the highest stroke rate in Europe? Well, they put it to the test, and, interestingly, there was a significant drop in men, compared to women. Maybe men are from Mars, women are from Snickers? 

Regardless, what about chocolate that’s not deep-fried? There’s been a few population studies that have followed people over time, and found that those who ate chocolate appeared to have lower stroke rates—since confirmed by another study. 

But, maybe chocolate consumption just happens to be related to other behaviors that are heart- and brain-healthy? Like hey, people that exercise a lot have to eat more food, period. So, maybe they eat more chocolate? They didn’t see any evidence of that, but you can’t account for everything. To prove cause and effect, you’d have to like randomize people into two groups, and make half eat chocolate, and the other half not, and follow them out for a decade or two—to which one researcher replied, fat chance; you try to get people into a study where they could be randomized to 16 years without chocolate. 

Friday, May 25, 2018

Razadyne For Alzheimer's

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Janssen Research & Development, LLC

Razadyne (galantamine) is an FDA-Approved daffodil extract for Alzheimer's. Check out the results of this study in which it significantly lowered mortality & eased cognitive decline.




An important study showed a significantly lower mortality rate in patients who were treated with galantamine, a prescription medicine for mild to moderately severe Alzheimer's disease, versus those who received placebo. Patients treated with galantamine also had significantly lesser decline in cognitive impairment after two years, compared to patients in the placebo group, according to investigators presenting the data at the American College of Neuropsychopharmacology 51st Annual Meeting in Hollywood, Fla. Janssen Research & Development, LLC, sponsored the study.

Galantamine is the generic name for the brand-name drugs Reminyl (UK) and Razadyne (USA). It is also spelled, "Galanthamine." In treating Alzheimer's, it competes with two similar drugs used to control levels of brain acetylcholinesterase in dementia patients.

These drugs are:

Brand NameGeneric Name
Aricept®donepezil
Exelon® or Ebixa®rivastigmine
Reminyl® or Razadyne®galantamine or galanthamine

Statistics Overview

At the study's final interim mortality analysis, an independent Data Safety Monitoring Board recommended early termination of the study due to an imbalance of deaths between the treatment group and the placebo group. Subsequent unblinding of the data indicated that mortality was statistically significantly lower in patients treated with galantamine, compared to patients who received placebo [3.1 percent versus 4.9 percent respectively; (P=0.021)]. In the final analysis, there was a total of 89 deaths; 33 (3.2 percent) in the galantamine group and 56 (5.5 percent) in the placebo group (P=0.011). 

The treatment group also had significantly lesser cognitive decline measured by the change from baseline in the Mini Mental Status Evaluation (MMSE) at month 24 of the study, compared to the group treated with placebo. The mean MMSE scores deteriorated from a baseline of 19 to 16.9 and 17.5 for the placebo and galantamine groups, respectively (P<0 .001="" a="" cognition.="" is="" measure="" mmse="" of="" span="" the="" validated="">

Additionally, there was a significantly greater decline from baseline in MMSE at month 6 in the placebo group compared with the galantamine group (P<0 .001="" 24="" activities="" as="" assessment="" baseline="" by="" change="" daily="" dementia="" disability="" from="" galantamine="" group="" in="" living="" measured="" month="" of="" placebo="" scores="" significantly="" span="" than="" the="" to="" was="" worse="">P=0.002). The DAD is a validated measure of activities of daily living.

About the Study

The randomized, double-blind, placebo-controlled clinical study was designed to evaluate the safety and efficacy of long-term (two-year) treatment with galantamine in patients with mild to moderately severe Alzheimer's disease. 

The primary safety endpoint was the rate of mortality or death over two years. The secondary safety endpoint was the incidence of treatment emergent adverse events, including serious adverse events, over two years.

Approximately 49 percent of the placebo group and 54 percent of the galantamine group reported at least one Treatment Emergent Adverse Event (TEAE). Approximately 12 percent of patients reported serious adverse events in both groups. Patients who were treated with galantamine reported numerically more TEAEs, most notably gastrointestinal disorders (nausea, vomiting). The incidence and types of serious AEs were similar in both groups, except for mortality, which was significantly higher in the group of patients that received placebo.

The primary efficacy endpoint was the change from baseline in the MMSE score at month 24. Secondary efficacy endpoints included cognitive change from baseline to month 6 as measured by the MMSE, and change in function from baseline to month 24 as measured by the DAD.

The trial enrolled 2,051 people (1,023 to the placebo group, 1,028 to the galantamine group) and was conducted at 127 sites in 13 countries. Patients in the study were between the ages of 45 and 92; their mean age was approximately 73 years. The majority of patients was female (65 percent).

The galantamine group initially received 8 mg of drug daily, and the dose was increased to 16 to 24 mg daily during the first 12 weeks of the study. Thereafter, patients were maintained on 16 to 24 mg of galantamine daily

Wednesday, May 23, 2018

Keep those with dementia safe by following these tips

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

The Alzheimer’s Disease Education and Referral (ADEAR) Center, a service of the National Institute on Aging, part of the National Institutes of Health.

Here are 20 ways to make your home a safer place for a loved one with dementia. 




While some Alzheimer's behaviors can be managed medically, many, such as wandering and agitation, cannot. It is more effective to change the person's surroundings—for example, to remove dangerous items—than to try to change behaviors. Changing the home environment can give the person more freedom to move around independently and safely. 

Minimize Danger

People with Alzheimer's disease may not see, smell, touch, hear, and/or taste things as they used to. You can do things around the house to make life safer and easier for the person. For example: 
  1. Check all rooms for adequate lighting. Use nightlights in bathrooms, bedrooms, and hallways.
  2. Be careful about small pets. The person may not see the pet and trip over it.
  3. Reset the water heater to 120 degrees Fahrenheit to prevent burns.
  4. Label hot-water faucets red and cold-water faucets blue, or write the words "hot" and "cold" near them.
  5. Install grab bars in the tub/shower and beside the toilet.
  6. Put signs near the oven, toaster, and other things that get hot. The sign could say, "Stop!" or "Don't Touch—Very Hot!"
You can also try these tips: 
  • Check foods in the refrigerator often. Throw out any that have gone bad.
  • Put away or lock up things like toothpaste, lotions, shampoos, rubbing alcohol, soap, or perfume. They may look and smell like food to a person with Alzheimer's.
  • If the person wears a hearing aid, check the batteries and settings often.

Basic Safety for Every Room

Add the following items to the person's home if they are not already in place: 
  • Smoke and carbon monoxide detectors in or near the kitchen and in all bedrooms
  • Emergency phone numbers and the person's address near all phones
  • Safety knobs and an automatic shut-off switch on the stove
  • Childproof plugs for unused electrical outlets and childproof latches on cabinet doors
You can buy home safety products at stores carrying hardware, electronics, medical supplies, and children's items. 

Lock up or remove these potentially dangerous items from the home: 

  1. Medicines
  2. Alcohol
  3. Cleaning and household products, such as paint thinner and matches
  4. Poisonous plants—contact the National Poison Control Center at 1-800-222-1222 or www.poison.org to find out which houseplants are poisonous.
  5. Guns and other weapons, scissors, knives, power tools, and machinery
  6. Gasoline cans and other dangerous items in the garage

Moving Around the House

Try these tips to prevent falls and injuries:
  1. Simplify the home. Too much furniture can make it hard to move around freely.
  2. Get rid of clutter, such as piles of newspapers and magazines.
  3. Have a sturdy handrail on stairways.
  4. Put carpet on stairs, or mark the edges of steps with brightly colored tape so the person can see them more easily.
  5. Put a gate across the stairs if the person has balance problems.
  6. Remove small throw rugs. Use rugs with nonskid backing instead.
  7. Make sure cords to electrical outlets are out of the way or tacked to baseboards.
  8. Clean up spills right away.
Make sure the person with Alzheimer's has good floor traction for walking. To make floors less slippery, leave floors unpolished or install nonskid strips. Shoes and slippers with good traction also help the person move around safely.

You may want to re-evaluate the safety of the person's home as behavior and abilities change.

For more home safety tips, see the NIH / National Institute on Aging's checklist: 

Monday, May 21, 2018

Dementia:Do NOT do theses things

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter



BIGJOURNEYsmallsteps

Whether caregiving for someone with Alzheimer's or just visiting, be wise & avoid these phrases. 





(

Saturday, May 19, 2018

What is HS-AGING?

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

University of Kentucky Sanders-Brown Center on Aging

3 important dementia studies focus on HS-AGING. It's a type of dementia almost as common as Alzheimer's in the 85+ group. Yet few people have heard of it. Why? What makes it different? 




In those who live to a very advanced age (beyond the age of 85) HS-AGING (hippocampal sclerosis in the elderly) is almost as prevalent as Alzheimer's. Remarkably, HS-Aging appears to be a completely separate disease from Alzheimer's, although it is almost always diagnosed as Alzheimer's disease while people are alive.

Three important papers authored by Dr. Peter Nelson and others at the University of Kentucky Sanders-Brown Center on Aging, explore the neuropathology behind this little-understood brain disease.

HS-AGING, much like Alzheimer's disease, causes symptoms of dementia, such as cognitive decline and impaired memory. Although Alzheimer's disease is probably the most recognized cause of dementia, HS-AGING also causes serious cognitive impairment in many older adults.

Overview of 3 New Studies on HS-AGING:

  1. The first paper, published in the Journal of Alzheimer's Disease, draws from a very large sample population and shows that presently, around 20% of all dementia cases are diagnosed as HS-AGING at autopsy, although almost none are given that diagnosis during life. That means that the presence of this disease is currently almost unknown by the health care providers who are seeing patients.
  2. A second study, "Arteriolosclerosis that affects multiple brain regions," appears in a recent issue of the journal Brain, and looks at small blood vessels in patients with HS-Aging and describes a specific change, called "arteriolosclerosis," which is present in patients with HS-Aging. This small blood vessel change may provide a new therapeutic target to alter the progression of the disease.
  3. Finally, the third paper, "Hippocampal sclerosis of aging, a prevalent and high morbidity brain disease," appears in Acta Neuropathologica and offers an overview of HS-AGING for patients and researchers. This paper reviews the relevant scientific literature and also presses home the point that HS-AGING is a very common disease that exerts a strongly adverse impact on public health.
It is important for physicians and scientists to understand the unique pathology of HS-AGING, and to be able to differentiate it from other diseases, as it is only by making an accurate diagnosis that clinicians can hope to treat people who present with signs of cognitive decline. These current studies represent a leap forward in the knowledge base about HS-AGING, and represent potential new paths to explore for diagnosis and treatment of this serious, but under-appreciated brain disease.

In people over 95, a type of dementia called HS-Aging is about as common as Alzheimer's. Yet few people have heard of it. Why? What makes it different?

What is HS-Aging?

HS-Aging stands for "Hippocampal Sclerosis in Aging People".

Alzheimer's and HS-Aging are types of dementia. In people over 95, their prevalence is about equal.

HS-Aging is Not Well Known. Everyone Has Heard of Alzheimer's. Why?

There are hundreds of types of dementia. In people aged 65 to 95, 60% of dementia cases are Alzheimer's. That is why Alzheimer's is so well-known.

At age 95, the balance shifts and HS-Aging becomes about as common as Alzheimer's.

Few people have heard of HS-Aging. The main reason is because it is often mis-diagnosed as Alzheimer's. Why?

When dementia is seen in the elderly, the default diagnosis is Alzheimer's. This is caused by many factors, among them:

  • Patients often do not want to go through extensive testing for a variety of reasons.
  • There is no simple test. The differences between dementias can be subtle. Therefore, distinguishing between dementias is often technically challenging.
  • Cost comes into play. For example, F18 dementia scans can run thousands of dollars. Therefore, many a diagnosis is made based on incomplete information.

With these realities, it is common for a diagnosis to default to the most common dementia, which is Alzheimer's.

As a result, people with dementias such as HS-Aging often live out their lives thinking they have Alzheimer's.

How does HS-Aging differ from Alzheimer's?

Alzheimer's and HS-Aging both damage the hippocampus. It seems that HS-Aging hits harder than Alzheimer's, causing greater disturbances to memory.

HS-Aging describes a brain under attack from a protein called TDP-43. It causes sclerosis, or the hardening of tissues. In the case of HS-Aging, TDP-43 proteins harden brain tissue in the hippocampus (sometimes called the memory-processing center), causing the loss of a large number of crucial brain cells. It is called Hippocampal Sclerosis because the brain's hippocampus is the focus of the attack.

Alzheimer's, on the other hand, is an attack on the brain by plaques (made from beta-amyloid) and tangles (made of tau proteins). Researchers speculate that the plaques clump together and "choke" brain cells, while the tangles strangle them from within.

How does HS-Aging differ from regular HS?

Regular Hippocampal Sclerosis (HS) occurs in younger people where brain tissue hardening is associated with epilepsy. HS-Aging is a similar hardening, but it occurs in the elderly with different consequences. It is caused by a long life of physical wear-and-tear on the brain, similar to vascular dementia. As a matter of fact, once people hit 95, the combined occurrences of HS-Aging PLUS vascular dementia actually outstrip Alzheimer's.

Why does the type of dementia matter?

As explained above, the biochemistry of each dementia differs significantly. This implies different medications are required to fight the chemicals causing the dementia. A person's response to medicines and supplements will be entirely different, depending on the disease.

Importantly, new F18 imaging techniques have recently been introduced that let doctors see if a person with dementia has the plaques associated with Alzheimer's. Using this technique helps doctors tell the difference between Alzheimer's and HS-Aging. This is particularly crucial in the world of clinical trials, where participants must closely match the experimental drugs they are testing.

CTE Research Leading to Rapid Improvements in HS-Aging Treatments

When we talk about dementia in aging athletes, it is usually the type of dementia called CTE (Chronic Traumatic Encephalopathy). Recent studies showed athletes in contact sports like football are 19 times more likely than average to develop dementia. As a result, there has been a huge burst of research on CTE treatment.

CTE treatment has a lot in common with HS-Aging treatment. With the new attention both of these dementias are now receiving, there is good reason to hope for effective new treatments in the immediate future.


MORE INFORMATION: 
Study #1 above was done with the collaboration of the National Alzheimer's Coordinating Center (or "NACC"; the first author of this study, Willa Brenowitz, is based in Washington state and works with NACC), enabling Nelson and colleagues to incorporate data from dozens of federally funded Alzheimer's Disease Centers around the country. These centers are funded by the National Institute on Aging, part of the National Institutes of Health. The research was supported by NIA grant numbers U01 AG016976 and P30 AG028383.

Study #2 above was based on analyses that were boosted through collaboration with the larger NACC-based dataset. Further, the first author, Dr. Janna Neltner, provided critical expertise in digital pathologic measurement of the brain. 

SOURCE:
University of Kentucky Sanders-Brown Center on Aging


Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info